Key characteristics

of rescue inhalers

3 Basic steps to use ProAir RespiClick®1

OPEN

Instructions for opening ProAir RespiClick (albuterol sulfate) inhalation powder
Make sure the cap is closed before each dose.

Hold the inhaler upright as you open the cap fully.

Open the cap all the way back until you hear a "click."

Your ProAir RespiClick® inhaler is now ready to use.

Do not open the cap unless you are taking a dose.

INHALE

How to inhale when using a dry powder inhaler

Breathe out through your mouth and push as much air from your lungs as you can.

Be careful not to breathe out into the inhaler mouthpiece.

Put the mouthpiece in your mouth and close your lips around it. Breathe in deeply through your mouth, until your lungs feel completely full of air.

Breathing in deeply through the mouthpiece will deliver the medication to your lungs.

Do not let your lips or fingers block the vent above the mouthpiece.

Hold your breath for about 10 seconds or as long as you comfortably can.

Remove the inhaler from your mouth.

Check the dose counter on the back of the inhaler to make sure you received the dose.

CLOSE

Completing your use of ProAir RespiClick (albuterol sulfate) inhalation powder
Always close the cap after each inhalation so your inhaler will be ready for your next dose.

If you need another dose close the cap and repeat all of the steps.

ProAir RespiClick® contains a powder and must be kept clean and dry at all times.
Resources
for your patients

Explore resources you can share with patients and caregivers

EXPLORE RESOURCES
Significantly greater efficacy with ProAir RespiClick® vs. placebo3

Find out about the efficacy of ProAir RespiClick® vs. placebo

CHECK OUT EFFICACY

Indications

ProAir RespiClick® (albuterol sulfate) Inhalation Powder is indicated in patients 4 years of age and older for the treatment or prevention of bronchospasm with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm.

Important Safety Information

  • ProAir RespiClick® (albuterol sulfate) Inhalation Powder is contraindicated in patients with hypersensitivity to albuterol or patients with a severe hypersensitivity to milk proteins. Rare cases of hypersensitivity reactions, including urticaria, angioedema, and rash have been reported after the use of albuterol sulfate. There have been reports of anaphylactic reactions in patients using inhalation therapies containing lactose
  • ProAir RespiClick® can produce paradoxical bronchospasm that may be life-threatening. Discontinue ProAir® RespiClick and institute alternative therapy if paradoxical bronchospasm occurs

Indications

ProAir RespiClick® (albuterol sulfate) Inhalation Powder is indicated in patients 4 years of age and older for the treatment or prevention of bronchospasm with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm.

Important Safety Information

  • ProAir RespiClick® (albuterol sulfate) Inhalation Powder is contraindicated in patients with hypersensitivity to albuterol or patients with a severe hypersensitivity to milk proteins. Rare cases of hypersensitivity reactions, including urticaria, angioedema, and rash have been reported after the use of albuterol sulfate. There have been reports of anaphylactic reactions in patients using inhalation therapies containing lactose

  • ProAir RespiClick® can produce paradoxical bronchospasm that may be life-threatening. Discontinue ProAir RespiClick® and institute alternative therapy if paradoxical bronchospasm occurs

  • Need for more doses of ProAir RespiClick® than usual may be a marker of acute or chronic deterioration of asthma and requires reevaluation of treatment

  • ProAir RespiClick® alone may not be adequate to control asthma in many patients. Early consideration should be given to adding anti-inflammatory agents, e.g., corticosteroids

  • ProAir RespiClick®, like other beta-adrenergic agonists, can produce clinically significant cardiovascular effects in some patients, as measured by heart rate, blood pressure, and/or symptoms. If such effects occur, the drug may need to be discontinued

  • ProAir RespiClick®, as with all sympathomimetic amines, should be used with caution in patients with cardiovascular disorders (especially coronary insufficiency, cardiac arrhythmias, and hypertension), convulsive disorders, hyperthyroidism, and diabetes

  • Fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs in patients with asthma. Do not exceed the recommended dose

  • Immediate hypersensitivity reactions may occur. Discontinue ProAir RespiClick® immediately

  • ProAir RespiClick® may produce significant hypokalemia in some patients, which has the potential to produce adverse cardiovascular effects. The decrease is usually transient, not requiring supplementation

  • Potential drug interactions can occur with beta-blockers, diuretics, digoxin, or monoamine oxidase inhibitors, and tricyclic antidepressants

  • In controlled studies of ProAir RespiClick® in patients 12 years of age and older, adverse events that occurred at an incidence rate of at least 1% and greater than placebo included back pain (2% vs 1%), pain (2% vs <1%), gastroenteritis viral (1% vs <1%), sinus headache (1% vs <1%), and urinary tract infection (1% vs <1%)

  • In controlled studies of ProAir RespiClick® in patients 4 to 11 years of age, adverse events that occurred at an incidence rate of at least 2% and greater than placebo included nasopharyngitis (2% vs 1%), oropharyngeal pain (2% vs 1%), and vomiting (3% vs 1%)

Please see full Prescribing Information.

REFERENCES

1. ProAir RespiClick Patient Information Leaflet. Horsham, PA: Teva Respiratory, LLC; April 2016. 2. Dolovich MB, Ahrens RC, Hess DR, et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest. 2005;127(1):335-371. 3. ProAir RespiClick Prescribing Information. Horsham, PA: Teva Respiratory, LLC; April 2016. 4. ProAir HFA Prescribing Information. Horsham, PA: Teva Respiratory, LLC; May 2012.